ClariTrial | Search Clinical Trials

Explore/Alzheimer's disease MCI prevention

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

26 results for “Alzheimer's disease MCI prevention” · Phase 3 · Phase 2

Page 1 of 2

Completed

Results posted

The Synapse Project

Phase 2Alzheimer Disease

UCB-JMRI ScanPET Scan

University of Wisconsin, Madison100 participants1 site · United StatesCompletes Oct 2023

Compare CT.gov Full analysis →

UNKNOWN

Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil - MICOIL

Phase 2Mild Cognitive Impairment

Freshly-Pressed Extra Virgin Olive Oilextra virgin olive oilmediterranean diet

Greek Alzheimer's Association and Related Disorders150 participants1 site · GreeceCompletes Feb 2018

Compare CT.gov Full analysis →

UNKNOWN

Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment

Phase 1Phase 2Mild Cognitive ImpairmentMild DementiaFasting-Mimicking Diet

Fasting-Mimicking Diet ProlonADTM

University of Genova40 participants3 sites · ItalyCompletes Aug 2023

Compare CT.gov Full analysis →

Terminated

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase 3Mild Cognitive ImpairmentAlzheimer's DiseaseDementia

Flutemetamol (Vizamyl)

University of Zurich11 participants1 site · SwitzerlandCompletes Dec 2019

Compare CT.gov Full analysis →

Completed

Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

Phase 2Phase 3Mild Cognitive Impairment

caloric restrictionomega-3 supplementationresveratrol supplementation+3 more

Charite University, Berlin, Germany330 participants1 site · GermanyCompletes Jul 2016

Compare CT.gov Full analysis →

Completed

Memory Impairment Study (Mild Cognitive Impairment Study)

Phase 3Alzheimer Disease

DonepezilVitamin E

National Institute on Aging (NIA)72 sites · United States, CanadaCompletes Jan 2004

Compare CT.gov Full analysis →

Active

Metformin in Alzheimer's Dementia Prevention

Phase 2Phase 3Mild Cognitive Impairment

Placebo oral tabletextended release metformin

Columbia University326 participants22 sites · United StatesCompletes Apr 2026

Compare CT.gov Full analysis →

Completed

Results posted

Metformin in Amnestic Mild Cognitive Impairment

Phase 2Mild Cognitive Impairment

MetforminPlacebo

Columbia University80 participants1 site · United StatesCompletes Feb 2012

Compare CT.gov Full analysis →

Completed

Results posted

The Efficient Brain Study

Phase 2Metabolism - Cerebral Energy

Fermented Papaya PreparationGranulated Sugar

University of Florida30 participants1 site · United StatesCompletes Jul 2018

Compare CT.gov Full analysis →

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

Compare CT.gov Full analysis →

Completed

Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia

Phase 2Alzheimer DiseaseCognitive Decline Due to Alzheimer DiseaseMild Cognitive Impairment Due to Alzheimer Disease

NaproxenPlacebo

Douglas Mental Health University Institute200 participants1 site · CanadaCompletes Mar 2017

Compare CT.gov Full analysis →

Recruiting

COMMETS- Combination MCI Metabolic Syndrome

Phase 2Alzheimer DiseaseMild Cognitive ImpairmentMetabolic Syndrome

SemaglutideIntranasal insulinSemaglutide placebo+1 more

Rutgers, The State University of New Jersey80 participants1 site · IsraelCompletes Dec 2027

Compare CT.gov Full analysis →

Terminated

Results posted

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CAD106 ImmunotherapyPlacebo to CAD106CNP520+2 more

Novartis Pharmaceuticals480 participants129 sites · United States, Australia, BelgiumCompletes Apr 2020

Compare CT.gov Full analysis →

Recruiting

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

Phase 2InsomniaCognitive DysfunctionMild Cognitive Impairment

SHUTi OASISPatient Education

University of Virginia144 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

UNKNOWN

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Phase 2Cognitive ImpairmentAlzheimer Disease

Lithium CarbonatePlacebo

University of Sao Paulo80 participants1 site · BrazilCompletes Mar 2009

Compare CT.gov Full analysis →

1–15 of 26

Explore/Alzheimer's disease MCI prevention

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

26 results for “Alzheimer's disease MCI prevention” · Phase 3 · Phase 2

Page 1 of 2

Completed

Results posted

The Synapse Project

Phase 2Alzheimer Disease

UCB-JMRI ScanPET Scan

University of Wisconsin, Madison100 participants1 site · United StatesCompletes Oct 2023

Compare CT.gov Full analysis →

UNKNOWN

Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil - MICOIL

Phase 2Mild Cognitive Impairment

Freshly-Pressed Extra Virgin Olive Oilextra virgin olive oilmediterranean diet

Greek Alzheimer's Association and Related Disorders150 participants1 site · GreeceCompletes Feb 2018

Compare CT.gov Full analysis →

UNKNOWN

Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment

Phase 1Phase 2Mild Cognitive ImpairmentMild DementiaFasting-Mimicking Diet

Fasting-Mimicking Diet ProlonADTM

University of Genova40 participants3 sites · ItalyCompletes Aug 2023

Compare CT.gov Full analysis →

Terminated

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase 3Mild Cognitive ImpairmentAlzheimer's DiseaseDementia

Flutemetamol (Vizamyl)

University of Zurich11 participants1 site · SwitzerlandCompletes Dec 2019

Compare CT.gov Full analysis →

Completed

Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

Phase 2Phase 3Mild Cognitive Impairment

caloric restrictionomega-3 supplementationresveratrol supplementation+3 more

Charite University, Berlin, Germany330 participants1 site · GermanyCompletes Jul 2016

Compare CT.gov Full analysis →

Completed

Memory Impairment Study (Mild Cognitive Impairment Study)

Phase 3Alzheimer Disease

DonepezilVitamin E

National Institute on Aging (NIA)72 sites · United States, CanadaCompletes Jan 2004

Compare CT.gov Full analysis →

Active

Metformin in Alzheimer's Dementia Prevention

Phase 2Phase 3Mild Cognitive Impairment

Placebo oral tabletextended release metformin

Columbia University326 participants22 sites · United StatesCompletes Apr 2026

Compare CT.gov Full analysis →

Completed

Results posted

Metformin in Amnestic Mild Cognitive Impairment

Phase 2Mild Cognitive Impairment

MetforminPlacebo

Columbia University80 participants1 site · United StatesCompletes Feb 2012

Compare CT.gov Full analysis →

Completed

Results posted

The Efficient Brain Study

Phase 2Metabolism - Cerebral Energy

Fermented Papaya PreparationGranulated Sugar

University of Florida30 participants1 site · United StatesCompletes Jul 2018

Compare CT.gov Full analysis →

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

Compare CT.gov Full analysis →

Completed

Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia

Phase 2Alzheimer DiseaseCognitive Decline Due to Alzheimer DiseaseMild Cognitive Impairment Due to Alzheimer Disease

NaproxenPlacebo

Douglas Mental Health University Institute200 participants1 site · CanadaCompletes Mar 2017

Compare CT.gov Full analysis →

Recruiting

COMMETS- Combination MCI Metabolic Syndrome

Phase 2Alzheimer DiseaseMild Cognitive ImpairmentMetabolic Syndrome

SemaglutideIntranasal insulinSemaglutide placebo+1 more

Rutgers, The State University of New Jersey80 participants1 site · IsraelCompletes Dec 2027

Compare CT.gov Full analysis →

Terminated

Results posted

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CAD106 ImmunotherapyPlacebo to CAD106CNP520+2 more

Novartis Pharmaceuticals480 participants129 sites · United States, Australia, BelgiumCompletes Apr 2020

Compare CT.gov Full analysis →

Recruiting

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

Phase 2InsomniaCognitive DysfunctionMild Cognitive Impairment

SHUTi OASISPatient Education

University of Virginia144 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

UNKNOWN

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Phase 2Cognitive ImpairmentAlzheimer Disease

Lithium CarbonatePlacebo

University of Sao Paulo80 participants1 site · BrazilCompletes Mar 2009

Compare CT.gov Full analysis →

1–15 of 26